Research Paper on:
AIDS Vaccine Pursuit

Unformatted Sample Text from the Research Paper:
cases have declined in the US and several other developed nations, but AIDS is still the scourge of much of Africa, India and China, threatening an entire generation in some  sections of Africa. AIDS was first described in 1981, and researchers have been seeking an effective vaccine for it ever since. Only one candidate has progressed to advanced  trial to date, however. A review of literature combining scientific and business information reveals that it is the business aspect of the AIDS  vaccine that has been most responsible for delay in achieving an effective vaccine. Global health organizations and nonprofit foundations call for greater private sector investment so that clinical trials  of existing formulations can progress. Introduction and Purpose It now has been more than 20  years since AIDS began to be described and for many of those years researchers have been striving to develop an effective vaccine against the disease that is being called the  scourge of Africa. Efforts to develop an effective vaccine largely have been unsuccessful, but recently the Associate Director of AIDS vaccines at the National Institutes of Health Margaret Johnston  reported that an effective vaccine likely will be available within the next decade (Researchers Say There Will Be An AIDS Vaccine Within 10 Years, 2001).  At the end of 2001, more than 9,000 individuals around the world were participating in clinical trials. This information is optimistic, but the fact remains that only  one potential vaccine has survived through advanced clinical trials to date (Vastag, 2001). Further, the trials themselves involve a great deal of time and it is unlikely that the